Everence Capital Management Inc. Invests $162,000 in Roivant Sciences Ltd. (NASDAQ:ROIV)

Everence Capital Management Inc. bought a new stake in Roivant Sciences Ltd. (NASDAQ:ROIV) in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm bought 13,680 shares of the company’s stock, valued at approximately $162,000.

A number of other institutional investors have also added to or reduced their stakes in ROIV. Arizona State Retirement System raised its stake in shares of Roivant Sciences by 31.5% in the second quarter. Arizona State Retirement System now owns 101,661 shares of the company’s stock valued at $1,075,000 after purchasing an additional 24,333 shares in the last quarter. Acadian Asset Management LLC raised its stake in shares of Roivant Sciences by 23.2% in the 2nd quarter. Acadian Asset Management LLC now owns 8,510 shares of the company’s stock valued at $89,000 after buying an additional 1,603 shares in the last quarter. United Services Automobile Association bought a new position in shares of Roivant Sciences during the 2nd quarter worth about $284,000. American Century Companies Inc. boosted its position in shares of Roivant Sciences by 26.5% during the 2nd quarter. American Century Companies Inc. now owns 81,422 shares of the company’s stock valued at $861,000 after acquiring an additional 17,074 shares in the last quarter. Finally, WINTON GROUP Ltd bought a new stake in Roivant Sciences in the second quarter valued at about $902,000. 64.76% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of research analysts have commented on ROIV shares. Cantor Fitzgerald restated an “overweight” rating on shares of Roivant Sciences in a research note on Thursday, September 19th. HC Wainwright reaffirmed a “buy” rating and issued a $18.00 price target on shares of Roivant Sciences in a research note on Wednesday, November 13th. One equities research analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company. According to data from MarketBeat.com, Roivant Sciences has an average rating of “Moderate Buy” and an average price target of $17.93.

Insider Buying and Selling at Roivant Sciences

In other Roivant Sciences news, COO Eric Venker sold 100,000 shares of the stock in a transaction on Wednesday, November 20th. The stock was sold at an average price of $11.32, for a total value of $1,132,000.00. Following the transaction, the chief operating officer now directly owns 606,525 shares in the company, valued at approximately $6,865,863. This trade represents a 14.15 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CIO Mayukh Sukhatme sold 689,495 shares of Roivant Sciences stock in a transaction on Thursday, December 26th. The shares were sold at an average price of $12.01, for a total value of $8,280,834.95. Following the completion of the sale, the executive now directly owns 18,836,547 shares of the company’s stock, valued at $226,226,929.47. This trade represents a 3.53 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders sold 1,942,629 shares of company stock worth $23,071,486. 7.90% of the stock is currently owned by corporate insiders.

Roivant Sciences Stock Performance

Shares of NASDAQ:ROIV opened at $11.02 on Friday. The business has a fifty day moving average of $11.89 and a 200-day moving average of $11.58. Roivant Sciences Ltd. has a twelve month low of $9.69 and a twelve month high of $13.06. The firm has a market cap of $8.02 billion, a PE ratio of 1.95 and a beta of 1.27.

Roivant Sciences Profile

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.